New treatments targeting epigenetic changes in Alzheimer's disease
Official title: New epigenetic inhibitors for Alzheimer's disease treatment
Funded at Massachusetts General Hospital · NIH-11116902 · Data updated 2026-11-12
This study is looking for new tiny molecules that can help block a specific enzyme to potentially improve memory and thinking skills in people with Alzheimer's disease by changing how certain genes work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 15, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $790,816 |
| NIH project number | 5R01AG086433-02 |
| Project ID | NIH-11116902 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing new small molecules that inhibit a specific enzyme (HDAC11) to potentially treat Alzheimer's disease. By modifying the epigenetic regulation of genes, the researchers aim to create compounds that can improve cognitive function in preclinical models of Alzheimer's. The project involves identifying and testing these compounds to find the most effective candidates for further development into drugs. If successful, this approach could lead to innovative therapies that address the underlying mechanisms of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from Alzheimer's disease, potentially improving their cognitive function and quality of life.
How similar studies have gone: Previous research has shown promise in using epigenetic approaches to treat neurological diseases, suggesting that this method could be a viable avenue for Alzheimer's treatment.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Wang, Changning — Massachusetts General Hospital
- Study coordinator: Wang, Changning
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.